Skip to main content

Page last checked

Research compound · not FDA-approved

Petrelintide

Also called ZP8396 or RO7895515.

Petrelintide is an experimental weekly shot for weight management. It copies the action of amylin, a hormone involved in fullness.

What matters first

Why people look it up
Researchers are studying Petrelintide for weight management.
What the evidence shows
Peer-reviewed Phase 1 trials reported weight loss. A separate Phase 2 poster reported a sponsor result. Petrelintide is not FDA approved.
Dose status
Petrelintide is not FDA-approved, so no dosing label exists for it. The sections below explain what researchers tested and what remains unknown.

Evidence snapshot

Published human trial

The fastest way to see what kind of evidence this page is built on.

Regulation
Not FDA-approvedNo US prescribing label
Dose source
Human study3 reported dose rows
Safety evidence
No listed safety findingsNo reactions reported here
Sources
5 cited sourcesMedical review complete · 2026-09-07
Open the shareable evidence image
Petrelintide at a glance: published human trial, dosing basis, regulatory status, safety coverage, and cited-source count. These details summarize the available sources; they are not treatment recommendations.

Further down: research and dosing details · how it works · how good the evidence is · questions

Medically reviewed by Kenneth Montecillo, MD2026-09-07open the primary sources

What is known about Petrelintide

Petrelintide is an experimental weekly shot for weight management. It copies the action of amylin, a hormone involved in fullness, and does not work through GLP-1. In two peer-reviewed Phase 1 trials, the largest reported average weight loss was 8.6% after 16 weeks. In a separate Phase 2 conference poster, the result reported by the company reached 10.7% at 42 weeks, compared with 1.7% with placebo. Petrelintide is not FDA-approved.

Petrelintide research and regulatory details: evidence quality, approval status, doses, handling, and presentation.
TopicValue
Strongest sourceHuman trial
FDA approvalNot FDA-approved
Studied dosing0.04–2.4 mg one subcutaneous dose in the Phase 1 single-dose study — from clinical trials
Studied dosing0.6–1.2 mg once weekly for six doses in Phase 1 — from clinical trials
Studied dosing2.4–9 mg once weekly for 16 doses in Phase 1, with study-set increases every two weeks to 2.4, 4.8 or 9 mg — from clinical trials
PresentationPetrelintide has no approved vial or mixing instructions; its studies use prepared research injections.

Every row links back to a source listed below. These facts are for reference, not a personal recommendation.

How Petrelintide works

Petrelintide acts at amylin. Here is what that means.

Amylin is not a gut hormone, and this is the one class here that does not act on a gut hormone receptor at all. Your pancreas releases amylin alongside insulin, and its job is to say the meal is over. Natural amylin clumps together and clears fast. A long-acting version is rebuilt to be stable enough for a weekly injection. It holds a signal that normally lasts one meal across several days.

◆ Receptor targets1 of 4 · amylin
5What each receptor does — 5 rows in the data table
Receptors targeted by Petrelintide, and what each receptor does
ReceptorPetrelintideWhat it does
GLP-1not targeted—
GIPnot targeted—
Glucagonnot targeted—
Amylintargetedarea postrema and hindbrainAmylin works mainly on a small brainstem region that sits outside the blood-brain barrier and samples the blood directly. Switching it on produces fullness — the feeling that ends a meal — rather than damping hunger in the gaps between meals. That is a different lever from the gut-hormone one.
Gastric and islet effectstargetedAmylin also slows stomach emptying and holds back the rise in glucagon after a meal, working alongside insulin on the same meal rather than repeating it.

The same four receptor groups are shown for every drug, so the differences are easy to compare. Targets come from the drug class. Any result specific to Petrelintide comes from the cited sources.

Amylin and GLP-1 signals help fullness in different ways. That is why researchers combine the two instead of only raising one dose. The side effects can also differ, so results from a GLP-1 drug do not automatically carry over to an amylin drug.

What the evidence for Petrelintide is

These numbers come from a study in people that was published in a peer-reviewed journal. The drug or dose may still be experimental and may not have FDA approval.

Human trial
What it establishes
The study gave known doses to a defined group, monitored what happened and compared the results with another group.
What it does not establish
One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

Read each result with the study length, dose and number of participants. Results from separate trials are not a direct comparison because the people and study designs differ.

Where Petrelintide is in clinical trials

9 registered studies; the program has reached phase 2, and 2 are still enrolling.

The soonest a running study expects to finish measuring people is April 2027. That is when the sponsor expects to finish collecting the main measurement. It is not a results date, and not a date anything goes on sale.

  • Phase 2Recruiting

    Phase II Clinical Trial to Evaluate the Efficacy and Safety of NV01-A02 in Children With Autism Spectrum Disorder

    Neuroventi Inc. · Autism Spectrum Disorder (ASD · 105 participants planned · started April 2025

    Main measurement due September 2025 (sponsor estimate)

    NCT06951854 on ClinicalTrials.gov

  • Phase 2Not yet recruiting

    A Dose-Finding Study of Petrelintide With Enicepatide (RO7795068) in Adults With Obesity or Overweight

    Hoffmann-La Roche · Obesity or Overweight · 486 participants planned · started September 2026

    Main measurement due November 2027 (sponsor estimate)

    NCT07589686 on ClinicalTrials.gov

  • Phase 2Running, closed to new participants

    Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

    Zealand Pharma · Overweight, Type 2 Diabetes · 221 participants · started April 2025

    Main measurement due August 2026 (sponsor estimate)

    NCT06926842 on ClinicalTrials.gov

A registered study means a sponsor filed a plan and started enrolling. It is not evidence the drug works, and most drugs tested in people never reach a pharmacy. Sponsors write and update these sources themselves; the National Library of Medicine publishes them without checking them.

ClinicalTrials.gov · retrieved 2026-09-07

Every compound we track, and what stage each one has reached →

Regulatory status

Petrelintide is investigational and has no FDA-approved product, prescribing schedule, retail price or availability date.

The results come from separate research studies and are group averages, not a forecast for one person. The Phase 2 result is conference material reported by the company, not a peer-reviewed paper.

Full regulatory tracker →

Where to go next on Petrelintide

Vial, water and dose for any peptide, with petrelintide as one example

U-100, U-50 and U-40 barrels each read differently, including petrelintide

MariTide on its own page, separate from petrelintide

MariTide has published human trial data, separate from petrelintide.

VK2735 in the full list, alongside petrelintide

No published half-life for VK2735, cited apart from petrelintide.

Survodutide in the full list, alongside petrelintide

No published half-life for survodutide, cited apart from petrelintide.

Tirzepatide on its own page, separate from petrelintide

Tirzepatide has an approved label, separate from petrelintide.

Brenipatide on its own page, separate from petrelintide

Brenipatide has no human dose shown to work, separate from petrelintide.

Enicepatide on its own page, separate from petrelintide

Enicepatide has published human trial data, separate from petrelintide.

What the zenagamtide page carries, separate from petrelintide

2 sourced zenagamtide reactions, on its own page, separate from petrelintide.

What the retatrutide page carries, separate from petrelintide

6 sourced retatrutide reactions, on its own page, separate from petrelintide.

Pemvidutide in the full list, alongside petrelintide

No published half-life for pemvidutide, cited apart from petrelintide.

Safety notes

  • Peer-reviewed Phase 1: nausea occurred in 16.7% to 33.3% of Petrelintide groups versus 16.7% with placebo
  • Sponsor Phase 2 poster: nausea occurred in 19.6% of pooled Petrelintide participants versus 6.2% with placebo
  • The sponsor poster reported gastrointestinal-event discontinuation in 1.5% of Petrelintide participants
  • No FDA-approved product, prescribing schedule, price or availability date exists

Questions about Petrelintide

Is Petrelintide FDA-approved?

No. There is no prescribing label for it, so no approved dose exists — the regulatory status section above has the detail.

How is Petrelintide taken?

By injection under the skin, one subcutaneous dose in the Phase 1 single-dose study.

How does Petrelintide differ from the other compounds in this class?

It acts at amylin. Adding or removing a receptor changes the effect. It also changes how much people can tolerate. These molecules are not swappable at the same number of milligrams. Comparing them milligram for milligram is the most common mistake in this category.

The nearest alternatives act elsewhere:

  • Tirzepatide (GIP + GLP-1)
  • Semaglutide (GLP-1 alone)
  • Liraglutide (GLP-1 alone)
  • Retatrutide (GIP + GLP-1 + glucagon)
  • Survodutide (glucagon + GLP-1)
  • Mazdutide (glucagon + GLP-1)
  • VK2735 (GIP + GLP-1)
  • Zenagamtide (GLP-1 + amylin)
  • Pemvidutide (glucagon + GLP-1)
  • Brenipatide (GIP + GLP-1)
  • Enicepatide (GIP + GLP-1)
  • MariTide (GIP + GLP-1)

What is not known about Petrelintide?

One trial cannot prove long-term safety or show that the result applies to everyone. The highest dose tested is a study dose, not a target for personal use.

5primary sources, each with the day we read it — open the documents used on this page